Oncofetal chondroitin sulfate (ofCS)

Oncofetal chondroitin sulfate is a unique linear glycosaminoglycan modification composed mainly of repeating disaccharide units (N-acetylgalactosamine and glucuronic acid) with a distinctive sulfation pattern and unusually long chain length[1][4]. It is minimally present in adult tissues, except in the placenta and fetal development, but is highly and aberrantly expressed in the majority of malignant solid tumors[1][4][10]. Oncofetal CS typically appears as a post-translational modification on various proteoglycans on the tumor cell surface, in the extracellular matrix, and in circulation. This molecule plays critical roles in tumor progression by contributing to cancer cell growth, migration, immune evasion, and matrix remodeling[1][8][10]. It interacts with signaling molecules, growth factors, and integrins, modulates tumor microenvironment, and is closely linked to poor prognosis in cancers. Its highly tumor-specific expression pattern has made it an emerging therapeutic target and biomarker in oncology, including use in investigational targeted therapies and diagnostics[2][4][10]. Current experimental approaches exploit its selective recognition by the malaria protein VAR2CSA and related binders to develop cancer-targeted therapies, such as bispecific T cell-engagers[2][10][8].\n\nNote: Oncofetal chondroitin sulfate is not a classical protein or gene but a specialized post-translational glycosaminoglycan structure, so it does not fit into traditional gene/protein target families such as “receptor” or “enzyme.” Its definition as a target derives from its molecular modifications and selective tumor cell expression[1][4][7].

Other names

oncofetal CSplacental-type chondroitin sulfate

Targeting ofCS enables cancer cell recognition or immune-mediated killing by T cells or other immune effectors (e.g., through bispecific T cell-engagers, anti-CS antibodies, or fusion proteins)[2][10].\nDisruption of cancer cell signaling, migration, and immune evasion by blocking or depleting ofCS from tumor cell surfaces[10][2].